Study pinpoints genetic variation that raises a risk linked to bisphosphonates
Friday, January 27, 2012 - 10:01
in Health & Medicine
Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors. The discovery paves the way for a genetic screening test to determine who can safely take these drugs. The study appears in the online version of the journal The Oncologist.